Veradermics reports promising late-stage results for new hair-loss pill
Updated
Updated · The Wall Street Journal · May 1
Veradermics reports promising late-stage results for new hair-loss pill
16 articles · Updated · The Wall Street Journal · May 1
The New Haven, Connecticut, company said patients grew more than four times as much new hair as placebo users, with about 80% reporting improvement within six months and no serious side effects.
The slow-release minoxidil formulation aims to avoid the cardiac-risk spikes linked to oral minoxidil and, if approved, would become the first new FDA-approved pill for pattern hair loss in nearly 30 years.
The drug is being tested separately in women, who currently have no approved hair-loss pills, as rivals including Cosmo, Kintor and Pelage also pursue new treatments for a market affecting roughly 80 million Americans.
With a $3B market forecast, will new hair loss drugs be a luxury for the rich or accessible to all?
Beyond better pills, are stem cell therapies the first real step toward a permanent cure for baldness?
As new drugs promise regrowth, what are the hidden long-term health risks of altering our natural biology?
Breakthrough Oral Treatment VDPHL01 Delivers 30-33 Hairs/cm² Increase in Hair Count with Rapid Onset and Excellent Safety
Overview
In April 2026, Veradermics announced positive Phase 2/3 trial results for VDPHL01, showing significant hair regrowth with a rapid onset and a strong safety profile free of cardiac and hormonal side effects. This breakthrough, enabled by its innovative extended-release formulation, led to a 47% surge in the company's stock and positioned VDPHL01 as a superior alternative to existing hair loss treatments. Ongoing trials aim to confirm efficacy in women, with FDA approval expected by 2027-2028. The drug's oral delivery also offers better patient adherence, promising to disrupt the $5 billion hair loss market while addressing unmet needs for safe, effective, and convenient therapies.